Eli Lilly Shares Dip Despite Barclays Overweight on Obesity Drugs
Eli Lilly shares fell after Barclays upgraded its obesity drug franchise to overweight, citing strong growth prospects for Mounjaro and Zepbound. Profit taking drove the stock down in afternoon trading despite the analyst’s bullish view on GLP-1 obesity therapies.
1. Barclays Upgrade and Market Reaction
Barclays raised its rating to overweight on Eli Lilly’s obesity drug franchise, highlighting robust demand for Mounjaro and Zepbound. Despite this positive outlook, profit taking drove shares lower in midday trading as investors booked gains.
Related News
GS
Goldman Sachs Warns of Record 8.7M bpd Oil Draws, Inventories at Eight-Year Low
GS•
URBN
Urban Outfitters Q1 Sales Soar 11% to $1.5B, EPS Up 12%
URBN•
FDS
Nvidia Q1 Revenue Soars 85% to $81.6B as Buyback Approved
FDS•
SLAB
Silicon Labs SoC Powers 500,000 Wi-SUN Module Shipment for India Grid
SLAB•
LCLN
Lincoln International Debuts 12.6% Up, Valued at $2.3 Billion After $421M IPO
LCLN•
Sources
F